Forward Pharma (FWP) Bullish Stance Reiterated at Jefferies Following Initial Interference Documents
View Older Stories
-
Acadia Pharmaceuticals (ACAD) PT Raised to $50 at Jefferies on Higher Nuplazid Sales Estimates
-
Neurocrine Bio. (NBIX) PT Raised to $39 at Jefferies
-
Neurocrine Bio. (NBIX) PT Raised to $32 at Jefferies
-
Jefferies Says Too Early to Judge the Impact of AbbVi Competition on Gilead (GILD)
-
Dynavax (DVAX) Bullish Stance Reiterated at Jefferies Following R&D Day
-
Jefferies Starts Neuroderm Ltd (NDRM) at Buy, $17 PT
-
Avanir (AVNR) Should Have Gotten at Least $26/Share in Takeover - Jefferies
-
Jefferies Starts Forward Pharma (FWP) at Buy
-
Competitor's IDO Partnership Bodes Well for Incyte (INCY), Jefferies Says
-
Completion of REDUCE-IT Best Way to Maximize Amarin (AMRN) Vascepa L-T Value, Jefferies Says
-
Auxilium (AUXL) Could Be Worth Up to $45/Share in a Potential Takeover - Jefferies
-
Auxilium Pharmaceuticals (AUXL) PT, Estimates Raised at Jefferies on Headcount Reduction
-
Arrowhead Research (ARWR) Bullish Stance Reiterated at Jefferies as ARC-520 Shows Highly Encouraging Efficacy
-
Jefferies Maintains Bullish Stance on Arena Pharma (ARNA) Despite Weaker Belviq Sales
-
Jefferies Starts La Jolla Pharma (LJPC) at Buy, Sees 166% Upside
-
Jefferies Starts Minerva Neurosciences (NERV) at Buy
-
Auxilium Pharmaceuticals (AUXL) Bullish Stance Reiterated at Jefferies Amid Authorized Generic Testim
-
Stemline Therapeutics (STML) PT Cut at Jefferies, Still Sees 288% Upside
-
Buy Incyte (INCY) Ahead of ASCO Abstract Release - Jefferies
-
Seattle Genetics (SGEN) 'Buy' Reiterated at Jefferies After Q1 Results and Ahead of Pipeline News
-
Neurocrine Bio. (NBIX) PT Trimmed at Jeffereis, 'Buy' Maintained
-
Revlimid Markman Briefing Documents Appear To Favor Celgene (CELG), Jefferies Says
-
Amarin (AMRN) Price Target Lifted at Jefferies on Kowa Deal
-
Incyte (INCY) Bullish Thesis Reiterated at Jefferies Post Physician Panel
-
Jefferies Starts Compugen (CGEN) at Buy
-
Dynavax (DVAX) 'Buy' Maintained at Jefferies Post Q4
-
Auxilium Pharmaceuticals (AUXL) Numbers Lifted at Jefferies Ahead of Q4 Earnings Print
-
Avanir (AVNR) Has Limited Upside Despite Likely Patent Trail Win, Jefferies Says
-
Jefferies Starts Dicerna Pharmaceuticals (DRNA) at Buy
-
Arrowhead Research (ARWR) Target Price Doubled at Jefferies
-
Biogen (BIIB) Target Price Lifted to $358 at Jefferies
-
Incyte (INCY) Target Price Lifted to $75 at Jefferies on IDO
-
Jefferies Starts Arrowhead Research (ARWR) at Buy
-
Jefferies Starts Mirati Therapeutics (MRTX) at Buy
-
Auxilium Pharmaceuticals (AUXL) PT Lifted to $30 at Jefferies on FDA Approval
-
OncoMed (OMED) Target Lifted to $46 at Jefferies after Celgene Deal
-
Arena Pharma (ARNA) Bullish Thesis Intact - Jefferies
-
Biogen (BIIB) PT Raised to $300 at Jefferies Post Q3
-
Jefferies Still Positive on Synta (SNTA) Despite Less Robust Data
-
Celgene (CELG) PT, Estimates Raised at Jefferies on 'Robust' Q3
-
Amarin (AMRN) PT Slashed to $4 at Jefferies
-
Amarin (AMRN) FDA Panel Predicted 7-to-3 in Favor of Approval - Jefferies
-
Net Positive on Amarin (AMRN) Into FDA Panel Vote - Jefferies
-
Biogen (BIIB) PT Raised at Jefferies Following National Hemophilia Foundation Meeting
-
Neurocrine Biosciences (NBIX) 'Buy' Rating Intact at Jefferies Despite Setback
-
Positive Feedback on Immunogen's (IMGN) IMGN-901 - Jefferies
-
Synta Pharma's (SNTA) Sees Encouraging Physician Feedback On Ganetespib - Jefferies
-
Rigel Pharma (RIGL) Plans to Shift Fostamatinib Focus From RA to ITP an 'Incremental Positive' - Jefferies
-
Jefferies Starts Stemline Therapeutics (STML) at Buy, Sees 77% Upside
-
CaPre to Have Minimal Impact on Amarin (AMRN) Vascepa Sales - Jefferies